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Reflections on the Report of the UN Secretary
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to Medicines
Reflexões sobre o Relatório do Secretário-Geral
das Nações Unidas do Painel de Alto Nível em
Acesso a Medicamentos

substantial financing ultimately coming from the
developed world. It is important to remember that
progress on access to HIV-AIDS treatment is the
result of a real political and economic struggle.
Strong advocacy remains at the heart of achieving
progress on access issues.
The HLP recommendations

Frederick M. Abbott 1
I am honored to be asked by Dr. Jorge Bermudez to
provide some additional commentary in reaction
to his essay regarding the way forward following
publication of the Report of the UN Secretary
General’s High Level Panel on Access to Medicines
(HLP). As a member of the Expert Advisory Group
(EAG) to the HLP I had the opportunity to participate in the meetings and dialogues in London,
Johannesburg and New York, and had a number
of opportunities to present my views.
The Report is in many ways a milestone
achievement. The HLP has called on governments,
international organizations, the private sector, the
science community and research institutions, and
civil society to adopt new approaches to the way in
which innovation and access are addressed. If the
HLP’s call for action makes its way into General
Assembly debate, and recommendations are more
generally taken up taken up, this could be the beginning of a transformation in the global approach
to innovation and access. The recommendations
are addressed, in any case, to a wide spectrum of
stakeholders that may act independently of the
General Assembly and its member states. Whether
the Report has an enduring impact naturally will
depend on what comes after, and that is what Dr.
Bermudez addresses in his essay. However, even as
a “standalone process”, the meetings and dialogues,
in conjunction with the many submissions, undoubtedly advanced the progress of ideas.
Strong advocacy remains essential
As Dr. Bermudez has pointed out, the HLP
Report fits within a series of developments at the
international level directed toward promoting
innovation in the pharmaceutical sector while
emphasizing the importance of assuring access
to the resulting treatments, preventives (such as
vaccines) and diagnostics. There have been some
very important successes, most notably the wide
expansion of access to HIV-AIDS treatments
brought about by sustained pressure from patient
advocacy groups, supported by developing country governments (including that of Brazil), with

The HLP Report makes a number of important
recommendations. Among these are insistence
that governments refrain from exerting pressures
against other governments in the course of trade
negotiations, or in the course of the implementation of laws, to limit measures to promote and
protect public health; that governments implement intellectual property laws, including patent
laws, in a manner that guards against the grant of
exclusive rights where not warranted by substantial
inventive contribution; that governments make
use of TRIPS Agreement flexibilities to promote
access, including by taking advantage of “quick,
fair, predictable and implementable” compulsory
licensing; that new models of innovation delinking
R&D costs from the price of medicines be pursued;
that the results of publicly funded research be
made widely available and accessible for use; that
governments, multilateral organizations and private sector companies must be more transparent
and accountable for the way in which innovation
and access is addressed, including through the
provision of specific information regarding R&D
costs and pricing, as well as clinical trial data and
accessible patent status information.
The phenomenon of exerting pressure in trade
negotiations to limit adoption and use of TRIPS
flexibilities, and subsequent pressure in specific
cases, started before the ink on the TRIPS Agreement dried (i.e., more than 20 years ago). This
is neither a secret nor a new development. But,
identification of the practice by the UN Secretary
General-appointed group, and a strong call for its
end, should bolster the position of governments on
the receiving end of pressure, and may give some
pause to the demandeurs. It is an incremental step,
but an important one.
Many of the submissions to the HLP were
directed toward new models for innovation,
including new mechanisms for financing. The
HLP recognized that problems with respect to
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An unfortunate reminder
I serve as Co-Chair of the Global Health Law
Committee (GHLC) of the International Law
Association. The GHLC made two submissions to
the HLP on behalf of its members. One of these
included proposal for establishing an essential
medicines patent pool (EMPP) that would initially request voluntary licensing, and incorporate
“effectively automatic” non-voluntary licensing
should voluntary licenses not be forthcoming.
Submission to the UN High Level Panel on Access
to Medicines by the Global Health Law Committee
of the International Law Association, Prepared by
Ellen ‘t Hoen LLM, Prof dr Brigit Toebes, Katrina
Perehudoff MSc, LLM, and Prof Frederick M
Abbott, Feb. 22. 2016. The compulsory licensing

provision was proposed to be implemented immediately, pending establishment of the EMPP
system, with the systems thereafter integrated.
For reasons that are not entirely clear, there was
a view expressed by some members of the HLP that
the proposal of “effectively automatic” compulsory
licensing would somehow be inconsistent with the
TRIPS Agreement, and in particular Article 31. Of
course, Article 31(a) provides that “authorization
of such use shall be considered on its individual
merits”. As noted in our submission to the HLP,
the Doha Declaration long ago confirmed that
“Each Member has the right to grant compulsory
licenses and the freedom to determine the grounds
upon which such licenses are granted.” There is
nothing in the TRIPS Agreement suggesting that
a determination by public health authorities that a
medicine is “essential” for the population, whether
at the national or at the WHO level, cannot be used
to determine the merits of granting an individual
compulsory license. To the contrary, it is difficult
to postulate a more compelling basis for such a
determination. In processing the request for a
compulsory license, the fact that a medicine has
been determined to be essential can and should
provide the grounds for an affirmative determination regarding the individual merits of that license.
There are other provisions of Article 31 that
would be addressed in constructing an “effectively
automatic” compulsory licensing mechanism for
essential medicines. In our brief submission to
the HLP, we observed that the refusal of a patent
holder to grant a voluntary license on the terms
established by the EMPP system would satisfy the
requirement that the grantee had attempted to
obtain a license on reasonable commercial terms
and conditions. By way of illustration, Canada’s
Access to Medicines Regime adopted to implement
the WTO August 30, 2003 waiver for export under
compulsory license uses a comparable mechanism.
We noted, of course, that government use and
emergency licenses do not in any case require an
effort to secure a voluntary license.
The GHLC is not alone in having proposed a
system for facilitating compulsory licenses for patented essential medicines. As a starting point for
resolving tensions between international trade and
IP rules, public health and human rights interests,
this frankly appears a relatively straightforward
and modest starting point.
Ultimately, a “sizable minority” of the HLP
would not agree to a proposal for effectively automatic compulsory licensing of essential medicines,
according to the Report, “because of concerns over
the potential incompatibility of such measures
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the relationship between innovation and pricing
are now of serious concern among high as well as
lower income countries, and that solutions must
be found. The Panel was somewhat cautious,
however, regarding proposals for new models of
innovation. The Report reflects concern that new
models might “break” the existing patent/market
exclusivity-based model without an adequate replacement, leaving the global community without
funding for research. Discussion in the Report
primarily focuses on antimicrobial resistance
(AMR) and neglected diseases. I might have been
more ambitious about new models because the
existing system already is broken. I do not think
the scientific community will abandon research on
new treatments for disease because capital markets in New York and Hong Kong are dissatisfied
with rates of return. Ways to fund research will be
found since the demand for treatments, vaccines
and diagnostics is not going away.
Each of the HLP recommendations reflects a
history of policy and legal identification and advocacy work. Notable is the demand for transparency
with respect to drug R&D costs, which have been
deliberately shrouded by the originator industry,
forcing policy-makers to guess at the legitimacy of
industry pricing practices. It is self-evident that the
R&D costs of major originator companies are wellknown and identifiable within those companies.
While it may be that predicting the success of any
given R&D project is difficult depending on the
nature of the project (e.g., harder with respect to
basic research, easier with respect to incremental
modification), the idea that major companies do
not keep careful books and records that enable
them to determine their actual R&D costs defies
common sense.
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with the TRIPS Agreement and the unintended
consequences that may result from such an approach. The High-Level Panel therefore did not
reach consensus on this particular issue”.
The issue of potential “unintended consequences” of several essential medicines-related
proposals had been discussed at some length at
the London Dialogue, including concern about
potential strategic gaming (including lobbying) of
essential medicines lists and the potential impact
on investments in innovation. These concerns tie
into broader issues regarding models of innovation and access. I do not believe that these concerns
justify impeding access to medicines that have
been determined to be “essential”, though this does
not mean these issues should not be addressed.
More concerning for present purposes is that a
group of Panel members used unfounded concern
regarding interpretation of the TRIPS agreement
as the basis for rejecting a proposal to facilitate
access to essential medicines. It is regrettable that
the Report went off in this direction. Yet, even here
there is an important lesson to be drawn from the
process. Namely, despite high-minded pronouncements that the TRIPS Agreement can and should
be interpreted to promote access to medicines for
all, the High Level Panel chartered by the UN Secretary General to address in coherencies between
public health, human rights, trade and intellectual

property rules became hung up on a debate about a
few words of the TRIPS Agreement -- a distraction
from meaningful change. This proves the point of
the UN Secretary General’s charter to the HLP:
conflict between IP, trade rules, human rights and
public health objectives remains to be resolved in
a convincing manner.
The way forward
As noted earlier, diverse stakeholders are addressed by the recommendations of the HLP, and
these stakeholders should pursue the recommendations in the Report. Beyond that, Governments
must be persuaded to take up the Report and its
recommendations in the UN General Assembly.
It may be useful to promote adoption of a UN
General Assembly Declaration embodying basic
principles on access to medicines so as to embed
the progressive ideas in the Report, and elsewhere
in the submissions, into the body of international
law. While such a Declaration might not have
the immediate impact of creating a new funding
mechanism, or in changing the terms of an already negotiated trade agreement, it might help
persuade legislatures and judges to prioritize the
right to health over narrow commercial interests,
and it might provide the basis for longer-term
systemic change.
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Comentário sobre o artigo de Jorge Bermudez
Mohga Kamal-Yanni 2
Thank you for inviting me to comment on the
article by Dr. Jorge Bermudez, which provides a
succinct overview of the debate on access to medicines as it progressed within the UN organizations and within the global trade system represented by the World Trade Organization (WTO).
The overview focuses on the High Level Panel
(HLP) and its report. My comment will centre on
the HLP and the follow up needed for the world
to benefit from its recommendations.
Dr Bermudez rightly emphasized the importance of access to medicines as a human rights’ issue and as a necessary pillar to achieve the SDGs.
The HLP on health technologies was established
by the UN Secretary General to “recommend
solutions for remedying the policy incoherence
between the justifiable rights of inventors, international human rights law, trade rules and public health in the context of health technologies”.
This aim carries a number of elements of critical
importance to access to medicines. For a start, it
does acknowledge the potential conflict o human
rights and intellectual property (IP) rules- even
though the US denies any such a conflict.
The right to health is enshrined in UN declarations and conventions since 19481. The Office
of the UN High Commissioner on Human Rights
clearly states that access to medicines is an entitlement of the right to health2. On the other hand
the right of the inventor is also recognized in the
HLP mandate as well as in the human rights declaration. However, the right of the inventor does
not equate IP rules. Inventors can be rewarded in
many ways including financial and non financial
compensations.
The aim of the HLP is carefully worded as
“policy coherence” rather than achieving “balance”. In my view, it is wrong to “balance” the human right to health with the IP so-called “rights”.
The human right to health, unlike IP “rights”, is
acknowledged as a natural right. The HLP clearly
states, “human rights are fundamental, universal
entitlements that people inherently acquire by
virtue of their birth”. “IP rights” are one policy
tool among many for encouraging innovation
and technological research and development
(R&D)”3.
The HLP is an important step on the path to
access to health technologies for a number of rea-

sons including its scope. Previous policy debates
focused on R&D for neglected diseases and prices
of medicines in developing countries. The HLP’
remit extends to all diseases and all health technologies in all countries. The price of medicines
is recognized as a global problem. In reality, there
is hardly a day that goes by without a media story about the high prices of medicines, especially
in the US, the country that heavily supports the
monopoly of pharmaceutical companies, which
leads to high prices. In Europe, where funding
for health services is mainly through tax, health
systems ration medicines or exclude expensive
medicines from national reimbursement4.
Dr Bermudez’s article also reminds us that
access to medicines is one of the health targets
of the Sustainable Development Goals (SDGs)5.
In fact, the HLP’ published consultations, and
especially its recommendations represent a serious step towards achieving the SDG health target
through its strong recommendations to incentivize innovation and affordable prices6.
On the innovation side, the HLP report emphasized proposals that have been already proposed through the work of WHO and of civil
society7,8. These include a strong focus on delinking the cost (and hence the funding of R&D)
from the price of the resulting products. This
is a critical recommendation because the pharmaceutical industry justifies the ever increasing
prices of medicines by the high cost they incur
in R&D. However, it is almost impossible to find
out the real cost of R&D for medicines because
of pharmaceutical companies’ secrecy. Therefore,
the HLP report also strongly recommends transparency on all aspects of R&D including on other costs that are normally included in the R&D
package such as marketing.
Deciding the global R&D agenda cannot be
left to market incentives. The current system,
based on IP monopoly, facilitates the highest possible profit to finance R&D, through the highest
price that a market can bear. The HLP report recommends increasing public financing for R&Da recommendation that both civil society and the
WHO have been promoting for decades. However, increasing public financing alone will not
produce affordable medicines without changing
the monopoly of the pharmaceutical industry
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because the new funds will end up in the old system producing the same high prices. Therefore,
affordable prices must be a contractual obligation for all public financing programs.
The HLP report proposed that the UN Secretary General starts a process for UN member
states to start negotiating an R&D agreement
on coordination, financing and development of
health technologies. The agreement needs to result in a binding convention that delinks the cost
of R&D from the price of the end product in order to promote access to health technologies for
all. The latest UN declaration on antimicrobial
resistance (AMR) signed by world leaders in September 2016, recommends delinking the cost of
R&D of antimicrobial medicines from price and
volume of the resulting products. We need to see
how this is translated into affordable antimicrobial medicines, diagnostics and vaccines.
On the access side, Dr Bermudez’s article
elucidates that the HLP made important recommendations, especially in emphasizing the importance of the Doha Declaration which places
public health before commercial interests. The
HLP report also recognizes the huge political
and economic pressures that countries face when
governments try to use the Declaration to implement measures such as compulsory licensing
to decrease the price of highly priced medicines.
The HLP report recommends that countries
lodge at the WTO any pressure they face from
other governments when they try to use the flexibilities enshrined in the Trade Related Aspects
on Intellectual Property Rights (TRIPS) agreement. Unfortunately the HLP report was not
bold enough to ban such pressure or to strongly request the WTO to treat such pressure as a
violation of the TRIPS agreement that requires
punitive sanctions.
The flourishing of Free Trade Agreements
(FTAs) greatly limits governments’ ability to use
the Doha declaration or any of the TRIPS flexibilities. The HLP report gives clear examples of
the limitations that are imposed on countries
through the FTAs. The proposed Trans Pacific
Partnership (TPP) is a prime example of FTAs,
which ratchet up IP protection and enforcement.
The HLP report acknowledges these TRIPS+

measures and their negative impact on public
health and calls for governments to conduct an
impact assessment before signing FTAs in order
to evaluate potential impact of the measures included in the agreement on public health. However, the Report falls short of condemning TRIPS
+ and of recommending a ban on including IP
in all bilateral and multilateral FTAs and treaties
Despite its shortcomings, the HLP report proposes important recommendations to enhance
access to health technologies. Yet the US government and pharmaceutical companies have been
attacking the HLP even before the report was
published. There is a great concern that the work
of the HLP could end up gathering dust on UN
shelves. Concerted advocacy by relevant stakeholders needs to be escalated in order to ensure
the implementation of the report’s recommendations.
The HIV story has taught us that political actions and real change require public campaigns
and vigorous advocacy. Civil society organizations play an important role in advocacy for pro
health global and national policies. Despite lack
of financial and human resources, there has been
a revival of the access to treatment movement
that campaigned for access to HIV medicines. As
the HLP report recommends, civil society organizations need to be funded in order to fulfill their
advocacy role for access to medicines. However,
this advocacy cannot be left only to civil society.
Members of the HLP and also the secretariat have
to play their part in demanding political action.
Yet the main actions must start from the UN
itself. The UN Secretary General, who established
the HLP in the first instance, needs to show his
public support for the HLP report and to set up
mechanisms to engage UN member states to
commence implementation of its recommendations - for example starting to negotiate an R&D
agreement. He should urge relevant UN bodies
and other multilateral organizations such as the
WTO to start implementing the recommendations relevant to their mandates.
Implementing the recommendations of the
HLP report is the first litmus test of the world
leaders’ serious commitments to the SDGs and
their pledge to leaving no one behind.
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Ensuring access; halting pressures!
Assegurando acesso; basta de pressões!
Claudia Vaca 3
Carolina Gómez 3
It is with great pleasure that we, people in the
developing world working on global public
health issues, receive the UN Secretary General´s
High Level Panel Report on Access to Medicines
(henceforth The Report). The importance of The
Report relies perhaps not so much in its contents
and recommendations, which of course are of the
outmost relevance, but on the fact that it stems
from the highest possible level at the UN System,
as Dr. Bermudez pointed out on his article.
Maybe it is not a coincidence that the concern
for the lack of access to medicines gained such
momentum when it became an issue for developed countries too. This is how Dr. Bermudez
mentions it: “Additionally the issue of access to
medicines and health technologies is no longer
considered as a problem or threat restricted to
low and middle-income countries, but is a problem that affects all human kind and also not restricted to a group of diseases. We are no longer
dealing with AIDS, TB and malaria or with the
so-called Neglected Tropical Diseases, but with
all diseases that affect human kind all over the
world, including chronic non-communicable
diseases.”
The debate sparkled by the price of Hepatitis
C medicines, the ever-increasing price of already
existing cancer medicines, the portrayal of some
types of cancers almost like orphan diseases (i.e.
market fragmentation) have started to put at risk
the financial sustainability of all healthcare systems of the world, regardless of their level of development. It is now evident, more than ever, that
the paradigm for incentivizing health innovation
is failing the rich and the poor of the world, even
though the High Level Panel could not reach a
consensus on this aspect.
We in the developing world, wonder what
needs to happen in order to reach such most
needed consensus. The WHO Global Strategy
and Plan of Action on Public Health, Innovation
and Intellectual Property and the CEWG managed to make it more or less politically correct
to sustain that failure exists for developing countries, regarding their diseases (mainly tropical,
communicable, infectious, neglected diseases).
Between CEWG and The Report shocking things
happened in the developed countries that would

make all think that it is now accepted that the
scope of the failure is wider: Sovaldi and its neverseen-before-sky-rocket-price came into the market and Spain, for instance, said that it could not
pay for it for all patients that need it, sparkling a
wave of social unrest and street demonstrations;
hundreds of US Oncologists wrote an open letter
warning about unpayable prices of cancer drugs;
the English Cancer Drugs Fund (CDF) ran out of
money. These are just some milestones that were
not enough to make the panel reach consensus.
Chikungunha, Zika and Ebola also happened in
the meantime, and we cannot avoid wondering
whether consensus would have been reached,
had those epidemics affected more people living
in the global north.
It is sad, but there is hope. Change does not
happen abruptly. Countries now need to push
the UN Secretary General, WHO, all other relevant UN agencies and the WTO to do something with The Report. A resolution accepting
and adopting it must be passed and the UN must
work to implement its recommendations and
also to help countries implement them. We need
to keep pushing, as we have done for about 20
years since the “Revised Drug Strategy”; we have
already come far, but not far enough. For a real
change to happen, consensus needs to be reached
on the failures of the current R&D system based
on legal monopolies (patents, data exclusivity) as
the main incentives for health innovation. Developed countries, that foster the companies that
have innovated, need to understand this.
As Dr. Bermudez correctly expresses it:
In all forums, we have to state clearly that we
cannot continue with a narrow scope of diseases or
addressing only low and middle-income countries,
but address all diseases and move the terminology
from neglected diseases to neglected populations
[...] If access to medicines is to be considered an
essential human right, further than voluntary and
compulsory licensing, the current IP system must
be profoundly discussed and changed.
We could not agree more: something fundamental in the way we innovate needs to change.
TRIPS flexibilities, especially compulsory licenses, are not the ideal solution the developing
world bargained for when it agreed to TRIPS
and to granting product patents for medicines.
Flexibilities have failed to deliver. Their promise
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time, the Ministry of Health decided there were
no merits for declaring Kaletra a medicine “of
public interest” (a previous step required in Colombia for a compulsory license) because, even
though it was proven that the price was high
compared to other countries, it was not being
paid directly by patients. At the time, the Ministry of Health seemed to be saying “price does not
matter, as long as the State can guarantee access”.
But things have changed dramatically in Colombia where price controls for medicines had been
introduced. Nowadays no ministry of health in
the world could take such a stand. Novartis, who
has been represented by the same lawyer that represented Abbott when the Kaletra case took place
in Colombia, quickly realized that that argument
would not work, and replaced it with other arguments.
But lets not loose track of the story line. Given the eminent disappearance of competition
and the extra financial burden for the healthcare
system, on November 2014, civil society organizations decided to trigger the process for the issuance of a compulsory license based on “public
interest reasons”, which is just one of the many
justifications allowed by the Colombian law for
a compulsory license. In our country, the process for this kind of compulsory licenses has
two phases: one at the ministry of health, who
declares that the health technology is “of public
interest”; the second one at the patent office who
issues the compulsory license and calculates the
royalties. Nobody knows, because it has never
happened (nor even tried out), whether the patent office can deny a compulsory license even
though MOH declared the medicine to be “of
public interest”.
Besides the juridical details and complexities of the case, the whole government, not just
the Ministry of Health was subject to enormous
amount of pressure by Novartis, Pharma, Switzerland, the USA and others, as mentioned in The
Report. Some of the letters pressuring Colombia
were leaked and some of them are published in
the MOH´s website (https://www.minsalud.gov.
co/salud/MT/Paginas/medicamentos-propiedad-intelectual.aspx). The Minister of Health
also received enormous amount of support from
civil society around the world: a letter signed by
hundreds of academics and activists was sent to
the President of Colombia. The US congress also
got involved and a letter of support by a number of Congressmen, including Senator and at
the time presidential candidate Bernard Sanders
was received. In sum, in Colombia, as in India,
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as the way embedded in the intellectual property
system (e.g. totally legitimate), to address public
health needs, is generally void. The rationale is
simple: compulsory licenses are an ad-hoc, caseby-case solution to a structural, systemic problem. This should not be understood as a call for
abandoning all attempts at compulsory licensing.
On the contrary, they are all we have now, so we
should embrace them, enable them, and make
them easier to use, as The Report does.
But, to illustrate our point, let us examine
more closely the case of Colombia, mentioned
both on the Report and on Dr. Bermudez´ article. In Colombia, the patent for imatinib was initially denied by the patent office in June of 2003.
Novartis then took the patent office to court and
won in February 2012, in part because the patent office did not litigate the case. During those
almost 10 years, several generics entered the market, but they had to exit once Novartis started enforcing its patent. Even though Novartis won the
case in court in 2012, they just started enforcing
their imatinib patent in 2014, right after the government had regulated, for the second time in the
previous 3 years, the price of Glivec, reducing it
in about 11%. Novartis claims that it took them
that long to double check that their competitors
were indeed infringing their patent (they bought
samples and analyzed them in order to prove
that the generic compound was the same as the
patented one). Nonetheless, NGOs have affirmed
that Novartis decision to enforce the patent is a
reaction to governmental price setting.
By 2014, 13 companies, including Novartis,
held marketing authorizations for imatinib in
Colombia. A difference of 198% was registerd
between the average price per milligram for all
imatinib generics (which ran between COP$50
per mg. and COP$98 per mg.) and Glivec (sold
at the time at COP$324 per mg.). Hence, the exit
of all those competitors from the Colombian
market and the sudden existence of a scenario
of monopoly after so many years of competition,
would have a considerable financial impact on
the public health budget. It is worth mentioning at this point that in Colombia, imatinib was
declared as an essential medicine in 2011 (years
before WHO did) and it is fully covered by the
public health insurance.
In fact, at the beginning of the process, Novartis made the argument that there were no real
access issues around imatinib because it was fully
covered. This argument had worked years before,
in the Kaletra case (the only other attempt for a
Compulsory License in Colombia) and at that
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the Glivec case transcended our territory and became a battlefield where titans clashed.
The pressure resulted in the delaying of the
decision and on division within the government.
Almost a year and a half after the initial request
was filed by civil society organizations, the Minister of Health, on July 2016, declared that imatinib was a medicine “of public interest”. Nonetheless, there will be no compulsory license, just
additional price controls. This decision is the
result of tough negotiations between the minister of trade and the patent office on the one
hand, and the ministry of health on the other.
The pressure and threats paid off. The trade sector of the government opposed the whole process especially because in the meantime Novartis
triggered the Investor- State Dispute Settlement
Mechanism contained in the Bilateral Investment
Treaty between Switzerland and Colombia. The
Deputy Director of the Patent Office issued a formal opinion, which was published by the Ministry of Health, arguing that in this case, given that
there were no merits for a “declaration of public
interest”, a compulsory license would amount
to an expropriation. The Colombian Constitution declares that there shall be no expropriation
without due compensation. Hence, he concluded, besides the royalty generics would have to pay
Novartis, the State would have to compensate the
company too.
At least the Minister of Health was able to
“save” the declaration of public interest, because the goal of Novartis was that not even that
would take place. This was due, majorly, to the
support by respected people and organizations
of the world, including WHO, whose deputy
director wrote a letter encouraging the Minister of Health and the UN high level panel, that
decided to mention the case on The Reprt. The
compromise reached between the sectors of the
government was that the declaration would be
issued, not for the purpose of a compulsory license, but for price controls that should be more
stringent than the ones currently in place. The
price for Glivec, it was agreed, should simulate
competition. The Minister has announced that
there would be additional price cuts for Glivec of
about 40% to 45%. This has not happened yet. In
Colombia, a commission is in charge of the control of prices of medicines. The minister of trade,
the minister of health and an appointee by the
president compose it. So the Minister had to take
the battle to this new scenario. A few weeks ago,
the commission issued, for public consultation,
a draft methodology for the regulation of prices

of medicines declared “of public interest” by the
Ministry of Health. It is based on international
reference pricing and the lowest price registered
in countries where branded and generics are sold,
will be the cap price in Colombia. The difference
between this method and the already existing one
is that this new one references prices of generics
which the old one does not, and it sets the price
at the lowest percentile, sets it at the 25th lowest
percentile.
If this method is adopted, then it will be applied to Glivec. The good news is that it is a general method, not an ad-hoc one just for Glivec.
The other good news is that given that in spite of
competition, Glivec still held 80% of the Colombian imatinib market, the savings for the health
care system might be grater than those obtained
if the competitors remain in the market, because
if a compulsory license was granted, they would
have to raise the prices to cover the royalties due
to Novartis.
Yet, this is still a speculation, because the new
price for Glivec has not been set and no doubt
Novartis will keep up the pressure. Civil Society
organizations that triggered the whole process
wonder whether this detour from a compulsory
license towards mandatory governmental price
controls was legal, because the norms that regulate the declaration of public interest explicitly
say such declaration is done for the purpose of a
compulsory license. Nonetheless, it seem a waste
of resources to fight that legal battle given the evident lack of political will by the patent office, the
ridiculous amount of time that litigation takes
in Colombia but specially, given the fact that the
patent will expire on June 2018. By the time some
sort of result is envisaged, the patent, if not expired yet, will be so close to doing so, that it is
expected that generic producer would rather wait
for it to expire than pay royalties to Novartis.
Thousands of pages could be written telling
all the details of this case. The point of writing
these ones down was to illustrate the hardships a
country must surmount to issue a compulsory license. All this energy, resources, time and political
capital invested in just one medicine, is it worth
it? From a public policy perspective, is it not possible to invest the same amount of resources aiming at having a wider impact? Given the current
R&D system, we are bound to these battles that
are worth fighting but that seem pointless, when
there are thousands of medicines all around that
should be accessible to all. For example, parallel to this enormous fight, the sells of nilotinib,
a me-too of imatinib with a considerable higher
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price, whose patent is also held by Novartis, have
been rising consistently in Colombia while those
of Glivec have lowered. Simply put: because the
patent for Glivec has started to expire around the
globe, Novartis has concentrated on promoting
nilotinib, which is still under patent and will sustain profits. This is proof of the distortions of our
innovation model, and, we repeat along with Dr.
Bermúdez, that unless something fundamental
changes, countries are just not simply equipped
to keep up just using compulsory licenses.
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Initially, I would like to acknowledge very much
the efforts and the solid background of the comments made by the eminent discussants on the
original text “Contemporary challenges on Access to Medicines: beyond the UNSG High-Level
Panel”.
Professor Frederick Abbott, the first discussant, very clearly spells the relevance of the HLP
Report as a milestone achievement, calling on all
stakeholders to move forward, beyond the UN
General Assembly. A series of developments addressing innovation and access within the pharmaceutical sector have seen important successes,
at the same time highlighting the relevance of
developments supported by developing country
governments.
Trade negotiations, pressures coming from
developed countries to limit the adoption of
TRIPS Flexibilities point to an immediate call for
its end. Submissions received by the HLP are also
mentioned seeking for new models for innovation, considering the current system as already
broken. The need to carefully weigh policy, legal
and advocacy work to ensure feasibility is at the
core of his comments.
The proposal for establishment of an essential medicines patent pool, incorporating voluntary licensing but at the same time ensuring incorporation of “effectively automatic” non-voluntary licensing is remarkably demystified with
solid legal arguments and regretting that the HLP
Report did not move further on exploring this
absolutely feasible proposal, as well as arguing
the need to discuss whereas a UN General Assembly Declaration would be a useful powerful
tool in prioritizing human rights over individual
commercial rights and pursuing a systemic longer-term change.
The second discussant, Dr. Mohga Kamal-Yanni, from OXFAM UK initially agrees on
the importance of addressing access to medicines
as a human rights’ issue and a link to the achievement of the SDGs, acknowledging the conflict
between human rights and IP as an individual
right. Very sharply, Mohga states as wrong to try
to balance human rights with IP as a right, as human rights must always prevail as natural rights.
Talking about innovation, she highlights the HLP

report on the work of WHO and civil society and
stresses the need to delink cost and price within
the pharmaceutical sector. Very correctively, we
are remembered that market incentives are not
adequate to decide the global R&D agenda and
she supports a binding convention which the UN
Secretary General is called to trigger a process for
discussion, further than the recent UN declaration recommending delinkage related to Antimicrobial Resistance (AMR).
Important recommendations are praised on
the HLP report, acknowledging the negative impact that TRIPS Plus provisions have on free trade
agreements. Some shortcomings of the report are
highlighted, including a stronger message requiring the banning of pressures on IP provisions on
bilateral or multilateral trade agreements.
Finally, the lessons learned with HIV are a
message that we need strong advocacy and public campaigns to ensure access as a human right,
so a multiple stakeholder initiative must follow a
strong push from the UN to really leave no one
behind on achieving the SDGs.
The third discussants, Drs. Claudia Vaca and
Carolina Gomez initially welcome the HLP Report and its importance for the developing world,
besides coming from the highest possible level at
the UN System. At the same time, they reaffirm
that the issues of access to medicines are no longer a restricted problem but affects all countries,
regardless of their level of development and this
has been a great change from previous discussion
restricted to the WHO forums. Examples and
milestones are correctly described by the discussants, especially the most recent examples that
have instigated this worldwide debate.
The discussants call for immediate changes
on implementing the HLP recommendations
and on discussing relevant issues elated to innovation, TRIPS Agreement, the failures on deliveries with TRIPS Flexibilities as not the ideal
solution to address public health needs.
A great contribution to the debate by Drs.
Vaca and Gomez is the indepth discussion on the
recent case of Colombia, mentioned in the HLP
and also in my article. The discussants share with
us details of the process involving Novartis, imatinib (Glivec) and generic versions and the difficulties faced by the Colombian Government on
attempting to publish a declaration of public in-
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Settlement Mechanism contained in bilateral investment agreements, which transfers the dispute
from WTO to a distinct forum, allowing even
companies to sue governments when they consider that private trade interests are being hampered with the issuing of governmental actions.
Anyway, the future is there to come, but the
implementation of concrete consensual recommendations, while at the same time, the debate
of ideas and proposals comes high in the international forums, must pave the way to the building
of a more equitable and solidarity future and a
better world for generations to come, leaving no
one behind.

Ciência & Saúde Coletiva, 22(8):2450-2451, 2017

terest by the Ministry of Health as an initial step
on the possibility of issuing a compulsory license.
This would be the first time of a case like this in
Colombia, with great external pressures to halt
this Government action.
Of special interest is being the discussion that
the discussants bring to this debate, including the
polemics intra-government and the “public interest” as a step not necessarily toward compulsory licensing but also aiming additional price controls. I must highlight that a sign of alert is very
clear from their comments and we need urgent
further debate on the impact and implications
of the triggering of the Investor-State Dispute

